There are currently 6 active clinical trials seeking participants for SARS-CoV-2 research studies. The states with the highest number of trials for Autism participants are Texas, Florida, California and New York.
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to <6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of th... Read More
Gender:
All
Ages:
Between 6 months and 5 years
Trial Updated:
04/23/2024
Locations: Trinity Clinical Research, LLC, Bessemer, Alabama +47 locations
Conditions: SARS-CoV-2
Register for Updates
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
NCT05954286
Recruiting
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland +4 locations
Conditions: SARS-CoV-2
Register for Updates
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
NCT05584202
Recruiting
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
Gender:
All
Ages:
Between 2 months and 6 months
Trial Updated:
03/12/2024
Locations: Trinity Clinical Research, LLC - Bessemer, Bessemer, Alabama +50 locations
Conditions: SARS-CoV-2
Register for Updates
Effectiveness and Use of COVID-19 Vaccines Using Information From the California State Vaccine Registry
NCT05876377
Recruiting
This study aims to use vaccination information from the California Immunization Registry linked with HealthVerity insurance claims for patients residing in California for the following: to measure effectiveness of the Pfizer-BioNTech bivalent booster against post-COVID conditions. to understand characteristics of patients who are receiving COVID-19 vaccines. All patients who have been de-identified in the HealthVerity database are eligible to be included for both aims of this study.
Gender:
All
Ages:
6 months and above
Trial Updated:
02/16/2024
Locations: Pfizer, New York, New York
Conditions: SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Register for Updates
A Study of the Effectiveness of Moderna COVID-19 Vaccine
NCT05933304
Recruiting
This is an observational cohort study to evaluate real-world vaccine effectiveness and durability of Moderna COVID-19 vaccine among a diverse population at Kaiser Permanente Southern California (KPSC). The primary objective of this study is to evaluate the vaccine effectiveness (VE) of receipt of Moderna COVID-19 vaccine in preventing SARS-CoV-2 infection and severe COVID-19 disease. SARS-CoV-2 infection will be defined as a positive antigen test result as well as a positive molecular diagnost... Read More
Gender:
All
Ages:
6 months and above
Trial Updated:
07/05/2023
Locations: Kaiser Permanente Southern California, Pasadena, California
Conditions: SARS-CoV-2, COVID-19
Register for Updates
Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment
NCT04918914
Recruiting
Abstract Background: Clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3). Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor. Methods: Patients who were... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/07/2021
Locations: Hunt Regional Medical Center, Greenville, Texas
Conditions: SARS-CoV-2, Hypoxia, ARDS
Register for Updates